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Purpose: Exosomes are small (30- to 100-nm)
vesicles secreted by all cell types in culture and found
in most body ﬂuids. A mean of 1 mL of blood serum,
derived from healthy donors, contains approximately
1012 exosomes. Depending on the disease, the number
of exosomes can ﬂuctuate. Concentration of exosomes
in the bloodstream and all other body ﬂuids is
extremely high. Several B-cell surface antigens
(CD19, CD20, CD22, CD23, CD24, CD37, CD40,
and HLA-DR) and the common leukocyte antigen
CD45 are interesting in terms of immunotherapy of
hematologic malignant neoplasms. The established
standard for exosome isolation is ultracentrifugation.
However, this method cannot discriminate between
exosome subpopulations and other nanovesicles. The
main purpose of this study was to characterize CD81þ
and CD63þ subpopulations of exosomes in terms of
these surface markers after release from various types
of B-cell lymphoma cell lines using an easy and
reliable method of immunomagnetic separation.
Methods: Western blotting, ﬂow cytometry, and
electron microscopy were used to compare the total
preenriched extracellular vesicle (EV) pool to each
fraction of vesicles after speciﬁc isolation, using
magnetic beads conjugated with antibodies raised
against the exosome markers CD63 and CD81.Accepted for publication May 16, 2014.
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June 2014Findings: Magnetic bead–based isolation is a con-
venient method to study and compare subpopulations
of exosomes released from B-cell lymphoma cells. The
data indicated that the speciﬁcally isolated vesicles
differed from the total preenriched EV pool. CD19,
CD20, CD24, CD37, and HLA-DR, but not CD22,
CD23, CD40, and CD45, are expressed on exosomes
from B-cell lymphoma cell lines with large hetero-
geneity among the different B-cell lymphoma cell lines.
Interestingly, these B-cell lymphoma–derived EVs are
able to rescue lymphoma cells from rituximab-induced
complement-dependent cytotoxicity.
Implications: Distribution of exosomes that contain
CD19, CD20, CD24, CD37, and HLA-DR may
intercept immunotherapy directed against these anti-
gens, which is important to be aware of for optimal
treatment. The use of an immunomagnetic separation
platform enables easy isolation and characterization of
exosome subpopulations for further studies of the
exosome biology to understand the potential for
therapeutic and diagnostic use. (Clin Ther.
2014;36:847–862) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
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Clinical TherapeuticsINTRODUCTION
The current understanding of the nature of exosomes is
that they are small (30- to 100-nm) cargo-containing
vesicles secreted by all cell types in culture. In addition,
exosomes have been found in body ﬂuids, such as blood,
saliva, urine, and breast milk.1 Exosomes have been
found to be involved in a variety of different biological
processes, such as antigen presentation,2 apoptosis,
angiogenesis, inﬂammation, and coagulation.3 They
can exchange proteins and lipids with target cells to
initiate downstream signaling pathways and deliver
speciﬁc nucleic acids.4–6 Exosomes are formed by a
process in which endosome membranes invaginate to
form vesicles inside the endosomal compartment, pro-
ducing multivesicular bodies (MVBs). They can contain
nucleic acids in the form of microRNA and mRNA,4,7–9
whereas less ribosomal RNA (rRNA) has been found.10
The protein composition of exosomes reﬂects their endo-
cytic origin in addition to their possible role in inter-
cellular communication.11 Exosomes contain proteins
from the membrane and fusion machinery (GTPases,
annexins, and ﬂotillin), MVB formation machinery (Alix
and TSG101), tetraspanins (CD9, CD63, CD81, and
CD82), heat shock proteins (Hsp70 and Hsp90), and
lipid-related proteins and phospholipases.12,13 The exo-
somal expression of these proteins is cell type dependent.
Isolation of exosomes is generally performed by
ultracentrifugation often in combination with sucrose
density gradients or sucrose cushions to ﬂoat the exo-
somes and thereby obtain high enrichment.14 Other, less
elaborate size-based isolation procedures have been
performed with ultraﬁltration protocols.15 Precipitation-
based protocols in combination with low-speed centrifu-
gation or ﬁltration have been reported to isolate all
exosomes in the sample.16–18 To obtain ultrapure exo-
some preparations or isolation of potential subpopula-
tion of exosomes, an immunomagnetic isolation strategy
can be applied by targeting exosomal markers.19,20
A large number of studies have reported that tumor-
derived exosomes can enhance cancer progression and
suppress immune responses. Interestingly, exosomes have
also been reported to contain oncogenes derived from
originating tumor host cells,21 indicating the possible use
of exosomes as samples for early detection of cancer
markers. The procancer effect of exosomes derived from
cancer host cells also affects the cancer treatment by
causing treatment resistance. It is well known that B cells
transformed with the Epstein-Barr virus contain large
numbers of MVBs, which spontaneously fuse with the848plasma membrane and release numerous exosomes,
containing molecules essential for the adaptive immune
response.22 Several components of the B-cell receptor
complex have been detected in extracellular vesicles
(EVs),23–25 which are vesicles shed from the plasma
membrane.26–29 The role of exosomes in B-cell biology
is potentially interesting for early diagnostic applica-
tions and in terms of their putative role in tumor
immunotherapy. Development of more potent vaccines
with exosomal targeting in some viral and parasitic
diseases has been suggested as a possible approach.30
Exosomal B-cell antigens might intercept immunother-
apy. Aung et al31 recently detected antigens that affect
established immunotherapy treatment (eg, expression
of CD20 on exosomes from B-cell lymphoma cells
correlates negatively with rituximab [anti-CD20] treat-
ment). The epitope-speciﬁc binding of anti-CD20 anti-
body was found to disturb the treatment with
rituximab, reducing the available antibodies binding
to the tumor cell in addition to complement consump-
tion and inhibition of complement-dependent cytolysis
of cancer cells.31 Interestingly, increased cytolytic
activity of rituximab against tumor cells was
observed after removal of the exosomes. A similar
scenario may also be possible for antibodies against
other B-cell surface antigens (eg, CD19, CD22, CD23,
CD37, CD40, and HLA-DR), which are currently in
clinical trials.32–34 This ﬁnding indicates that targeting
the exosomes would be advantageous to increase the
efﬁcacy of therapeutic antibodies.
The aim of our study was to establish an easy and
reliable method to characterize subpopulations of exo-
somes released from different cell lines that represent
various types of B-cell lymphoma. We analyzed the
expression of 9 different B-cell surface proteins (CD19,
CD20, CD22, CD23, CD24, CD37, CD40, CD45, and
HLA-DR), which are interesting in terms of immuno-
therapy for depletion of B cells and hematologic malig-
nant neoplasms.32–39 Using this method, we characterized
differences in protein composition between exosomes
derived from different sources and found heterogeneity
in the exosomal expression of B-cell surface antigens
among B-cell lymphoma cell lines. We found that EVs
derived from lymphoma cells are able to intercept
rituximab-induced complement-dependent cytotoxicity
(CDC). In addition, CD19, CD20, CD24, CD37, and
HLA-DR were detected in different exosome populations
released from B-cell lymphoma cells, which can have an
effect on immunotherapy.Volume 36 Number 6
M.P. Oksvold et al.MATERIALS AND METHODS
Reagents
For isolation of CD63þ exosomes, magnetic beads
coated with monoclonal anti-human CD63 were used
(Exosome-Human CD63 Isolation/Detection; Life
Technologies, Oslo, Norway). For isolation of
CD81þ exosomes, magnetic beads coated with mono-
clonal anti-human CD81 (Life Technologies) were
applied. The primary antibodies for Western blotting
analysis were as follows: mouse anti-CD81 (sc-7637),
anti-CD9 (sc-59140), anti-CD45 (sc-1178), and anti-
HLA-DR (sc-53319) and goat anti-CD19 (sc-8498)
and anti-CD20 (sc-7733) (Santa Cruz Biotechnology,
Santa Cruz, California). Mouse anti-human CD63
(antibody 59479) was obtained from Abcam (Cam-
bridge, Massachusetts). The primary antibodies for
ﬂow cytometry were as follows: mouse anti-human
CD9 phycoerythrin (PE) (555372), anti-human CD63
PE (556020), anti-human CD81 PE (555676), anti-
human CD22 antigen-presenting cell (APC) (333145),
anti-human CD23 PE (561774), anti-human CD24 PE
(555428), and anti-human CD40 APC (555591) (all
from BD Biosciences, San Jose, California). Anti-
human CD19 Alexa-488 (MHCD1920), anti-human
CD45 APC (MHCD4505), and anti-human irrelevant
isotype-matched APC-labeled monoclonal antibodies
(MG105) were purchased from Invitrogen (Carlsbad,
California). Anti-human CD20 PE (R7013) was ob-
tained from Dako (Carpinteria, California), and anti-
human HLA-DR ﬂuorescein isothiocyanate (FITC)
was from eBioscience (San Diego, California). Mouse
anti-human CD37 (HH1), originally developed in our
laboratory,40 was obtained from Diatec Monoclonals
AS (Oslo, Norway) and Nordic Nanovector (Oslo,
Norway) and coupled to Alexa-647. Horseradish
peroxidase–coupled goat anti-rabbit IgG and rabbit
anti-mouse IgG and anti-goat IgG were obtained from
Dako. Horseradish peroxidase–coupled anti-mouse
IgG Trueblot was purchased from eBioscience.
Protein-A gold was obtained from CMC (Utrecht,
Netherlands). All other reagents were from Sigma-
Aldrich (St. Louis, Missouri) unless otherwise noted.
Cell Culture
The B-cell lymphoma cell lines Ramos, SUDHL-4,
SUDHL-6, and Ros-50 were maintained in RPMI 1640
(PAA, Pasching, Austria) supplemented with 10% fetal
bovine serum (FBS; Lonza, Basel, Switzerland), penicillin,
and streptomycin. The colon adenocarcinoma SW480June 2014cell line was maintained in RPMI 1640 (Lonza), supple-
mented with 10% FBS (Gibco, Carlsbad, California), L-
glutamine, and 0.01% sodium pyruvate. Cells were
routinely tested for mycoplasma (Venor GeM; Minerva
Biolabs, Berlin, Germany).
Exosome Extraction From Cell Media
Before harvesting exosomes, the cell culture medium
was replaced with fresh complete medium with FBS for
24 hours. Ramos, SUDHL-4, SUDHL-6, and Ros-50
cells (1  108) and SW480 cells (5  107) were cultured
for each exosome sample preparation. After 24 hours,
cells and debris were removed by centrifugation at 350g
for 10 minutes and 2000g for 30 minutes. The Total
Exosome Isolation Kit (Life Technologies) was added to
the cell and debris-free cell medium (1:2 with exosome
isolation reagent and cell medium, respectively). Cell
medium and the exosome isolation reagent were mixed
by brief vortexing and incubated at 41C overnight before
centrifugation at 41C at 10,000g for 1 hour. The pellet
that contained preenriched exosomes was resuspended
in phosphate-buffered saline (PBS) (eg, 400 mL for 10
mL of cell media input). During all exosome sample
preparations, negative controls were made from the
corresponding complete medium with FBS. Before anal-
ysis of preenriched exosome samples, total protein level
was measured using Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, California) and Sunrise micro-
plate absorbance reader (Tecan, Männedorf, Switzer-
land) and adjusted to equal total protein concentrations.
Size of Exosomes
Analysis of preenriched exosomes was performed
using the NanoSight LM10 instrument (Malvern
Instruments Company, Nanosight, Malvern, United
Kingdom), following the manufacturer’s protocol.
Precipitated exosomes from the culture media of 50
 106 SW480 cells were resuspended in 1 mL of PBS.
Input was 5 mL, and measurement volume was 1 mL.
Real-Time Quantitative Polymerase Chain
Reaction
RNA isolation, reverse transcription, and real-time
quantitative polymerase chain reaction analysis were
performed as previously described.41 The following
primers were used for the experiment: Hs99999905_m1
(GAPDH), Hs03023880_g1 (ACTB), Hs99999901_s1
(18S), has-let-7a, 000377 (Let7a), and has-miR-16,
000391 (miR16).849
Clinical TherapeuticsImmunolabeling of EVs for Ultrastructural
Analysis
Preenriched EVs (5 μL) were placed on carbon-
coated copper grids and incubated for 15 minutes at
room temperature followed by blocking with 0.5%
bovine serum albumin (BSA) in PBS for 10 minutes and
embedded in methylcellulose. A standard immunogold
labeling procedure42 that targeted CD81 was per-
formed. Then EVs were analyzed at the Unit of
Cellular Electron Microscopy, Oslo University Hos-
pital, on a JEOL JEM 1230 transmission electron
microscope (Jeol Ltd, Tokyo, Japan). Images were
recorded at 80 kV using a Morada camera and iTEM
software (Olympus, Tokyo, Japan). Further image
processing was performed with Adobe Photoshop
software (Adobe Systems, San Jose, California).
Preparations of Total Cell Samples for Western
Immunoblotting Analysis
Cells were lysed and processed for SDS-PAGE as
described previously.43 SuperSignal West Dura or
Femto (Thermo Scientiﬁc, Waltham, Massachusetts)
was used for detection. Chemidoc MP (Bio-Rad Labo-
ratories) or Hyperﬁlm (GE Healthcare, Buckinghamshire,
England) were applied for imaging.
Preparation of Preenriched Exosomes for
Western Immunoblotting Analysis
The total preenriched exosome sample was diluted
1:1 in PBS, 5 RIPA lysis buffer and proteinase
inhibitor (F. Hoffmann-La Roche AG, Basel, Switzer-
land) was added, and the sample was incubated at 41C
for 15 minutes. The lysed exosomes sample was mixed
1:1 with 2 Tris lysis buffer (pH 6.8) under reducing
or nonreducing conditions. Samples were further
processed for SDS-PAGE.
Preparation of immunoisolated Exosomes for
Western Immunoblotting Analysis
The total preenriched exosome sample was diluted
1:1 in PBS with 0.1% BSA. Magnetic beads coated
with anti-human CD63 or anti-human CD81 (200 mL
of 2  106 immunomagnetic beads) were prewashed,
mixed with the exosome sample, and incubated over-
night at 41C while mixing. The beads were washed in
PBS with 0.1% BSA and lysed in 25 mL of RIPA buffer
(150 mM sodium chloride, 1.0% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH
8.0) with proteinase inhibitors followed by 15-minute850incubation on ice. The lysate was mixed 1:1 with 2
Tris lysis buffer under reducing or nonreducing con-
ditions. Samples were further processed for SDS-
PAGE.
Preparation of Exosomes on Immunomagnetic
Beads for Electron Microscopy
Immunomagnetic beads coated with anti-human
CD81 (50 mL) were mixed with total preenriched
exosome sample (250 mL) followed by overnight
incubation at 41C. The sample was centrifuged shortly
on a table centrifuge to collect all material. Then PBS
with 0.1% BSA (500 μL) was added to the sample
followed by mixing. The tube was then applied to a
magnetic ﬁeld and supernatant was removed.
Electron Microscopy
For conventional Epon embedding and sectioning,
exosomes isolated with immunomagnetic beads
coated with anti-human CD81 were ﬁxed in 1%
glutaraldehyde in 200 mM cacodylate buffer (pH
7.4) for 1 hour, washed repeatedly in dH2O, and
incubated in cacodylate buffer that contained 1.5%
potassium ferricyanide and 1% osmium tetroxide for
1 hour. After 2 subsequent 30-minute incubations in
1% tannic acid and 1.5% magnesium uranyl acetate,
the samples were dehydrated by using ethanol and
embedded in Epon. Ultrathin sections were prepared
and stained with lead citrate. Sections were analyzed
on a Philips CM100 (Electron Microscopy Unit for
Biological Sciences, University of Oslo).
Flow Cytometry
Subpopulations of exosomes were isolated from
total preenriched exosome samples using immunomag-
netic beads coated with anti-human CD81. The beads
(20 mL) were washed before adding preenriched exo-
some sample (100 mL) and PBS with 0.1% BSA (150
mL). The beads were incubated overnight at 21C to 81C
while mixing. After incubation, the beads were washed
by using magnet separation and PBS with 0.1% BSA.
After washing, beads were resuspended in 300 mL of
PBS with 0.1% BSA. A volume of 100 mL was used for
each ﬂow staining and incubated for 45 to 60 minutes
in a shaker (1050 rpm) at room temperature followed
by washing and ﬂow cytometric analysis using
ﬂuorescence-activated cell sorting (FACS) (BD FACS-
Canto II, BD Biosciences and Cytobank Inc, Menlo
Park, California).Volume 36 Number 6
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SUDHL-6 cells (2  105 per well in a 96-well plate)
cultured with complete RPMI 1640 with noninacti-
vated human serum (20%) were incubated or not with
precipitated EVs (10-20 mg/mL) derived from SUDHL-
6 or SW480 cells and then rituximab was added (1 mg/
mL). The cells were incubated for 1 hour and then
incubated with 20 mL of CellTiter 96 Aqueous One
Solution reagent (Promega, Fitchburg, Wisconsin) for
1 hour. Absorbance at 490 nm was measured in a
Sunrise 96-well plate reader (Tecan).
RESULTS
Analysis of Exosome Markers and B-Cell
Surface Antigens in Cells
To characterize exosomes from different B-cell
lymphoma cells, we ﬁrst analyzed the expression of
classic exosomal markers and B-cell surface antigens
in cells by Western immunoblotting of total cell lysates
and by ﬂow cytometry at the single-cell level. CD9,
CD63, and CD81, members of the tetraspanin family
of proteins, are frequently located at the exosome
surface.11,44–46 Chiba et al47 found that the tetraspa-
nin protein family (CD9, CD63, and CD81) was a
useful collection of markers of exosomes derived from
colorectal cancer cell lines, including SW480. The
SW480 cell line was therefore chosen as a positive
control for exosomal markers. Furthermore, exosomes
derived from SW480 were used as negative controls
for the analysis of B-cell surface protein because of the
lack of CD19 and CD20, surface molecules that are
expressed in all B-lineage cells.48
CD63 and CD81 were detected in lysates from all
cell lines. CD81 expression was low in SW480
compared with B-cell lymphoma cell lines, CD63
expression was low in SUDHL-6 cells and highest in
SW480 cells, and CD9 was expressed only in SW480
cells (Figure 1A), as expected. Expression of the 4
different B-cell surface antigens (CD19, CD20, CD45,
and HLA-DR) was detected in all B-cell lymphoma
cell lines, except HLA-DR, which was absent or
weakly expressed in Ramos cells (Figure 1A) in
agreement with previous ﬁndings.32 Different CD45
isoforms were detected, which has previously been
described in B-cell lymphoma cells.49 Furthermore,
CD45 is heavily glycosylated, which can explain the
observed smearing of CD45 (Figure 1A). As expected,
expression of B-cell surface antigens was not detected
in SW480 cells. Flow cytometry was applied toJune 2014characterize the expression of 5 additional B-cell
surface antigens (CD22, CD23, CD24, CD37, and
CD40) in the different B-cell lymphoma cell lines
(Figure 1B). CD37 was highly expressed in all cell
lines (Figure 1B), whereas expression of CD24 was
detected in 2 of the cell lines (SUDHL-6 and Ros-50).
CD22 was well expressed in all cell lines, CD40 was
moderately expressed, and CD23 was weakly
expressed.
Analysis of Exosome Markers and B-Cell Surface
Antigens in Preenriched Exosome Samples
Next, exosomes were preenriched by precipitation
and centrifugation of cell culture supernatants har-
vested from cells in culture for 24 hours. The size
distribution of the precipitated exosomes from SW480
cell culture media was analyzed using the NanoSight
LM10 instrument, which had a size range (maximum,
102 nm) comparable to standard exosome prepara-
tions by ultracentrifugation (Figure 2A). Furthermore,
to verify that precipitated exosomes were comparable
in terms of RNA content, the precipitated exosomes
originating from the SW480 cells were analyzed
for mRNA, rRNA, and microRNA content. In agree-
ment with earlier studies,4,8 the precipitated exosomes
contained full-length mRNA and rRNA (GAPDH and
18S) and microRNAs (ACTb, Let7a, and miR16),
which are typical for exosomes (Figure 2B). To
conﬁrm the identity of these vesicles, the preenric-
hed samples were subjected to immunolabeling follo-
wed by contrasting before ultrastructural analysis.
Preenriched exosome samples were prepared from all
4 different B-cell lymphoma cell lines in addition to
SW480 cells. In this approach, only antigens located
on the surface of the exosomes are available for
antibody binding, such as the tetraspanin protein
CD81, commonly identiﬁed in exosomal prepara-
tions.50 Ultrastructural analysis conﬁrmed that the
observed vesicles represented exosomes in terms of
size and expression of CD81 (Figure 2C). These
preenriched exosomes, which had a homogenous size
distribution as previously reported,41 were present in
the culture media from all 5 different cell types
analyzed.
Lysates of the preenriched exosome samples were
then analyzed in more detail for expression of B-cell
surface proteins and exosome markers by Western
immunoblotting. Our complete RPMI media with FBS
was analyzed for possible contents of exosomes. The851
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Figure 1. Expression of B-cell surface proteins and exosomal markers. (A) Total cell lysates from 4 different
B-cell lymphoma cell lines (Ramos, SUDHL-4, SUDHL6, and Ros-50) and SW480 cells were lysed
and processed for Western immunoblotting analysis. Expression of the B-cell surface proteins
(CD19, CD20, CD45, and HLA-DR) and exosomal proteins (CD9, CD63, and CD81) were studied.
β-Tubulin was applied as the loading control. One of 3 representative experiments is shown. (B)
Cells were stained with a panel of antibodies against B-cell surface proteins (CD22, CD23, CD24,
CD37, and CD40) or irrelevant control antibodies on ice for 30 minutes. Median fluorescence
intensity (arcsinh ratio of medians) relative to irrelevant control is shown. Fluorescence-activated
cell sorting (FACS) analysis was performed on singlet cells using BD FACSCanto II. One of 3
representative experiments is shown. APC ¼ antigen-presenting cell; FITC ¼ fluorescein isothio-
cyanate; PE ¼ phycoerythrin.
Clinical Therapeuticsexosome markers human CD81 and CD63 were not
detected in precipitates from complete RPMI media
with FBS, but precipitates from the same culture
media incubated with cells for 24 hours contained
CD81 and CD63 (Figure 3A). Total expression of
CD81 and CD63 was also compared between the
ultracentrifuged and precipitated exosomes, which
had an expression comparable to these exosome
markers (Figure 3B). The abundance of HLA-DR in
preenriched exosome samples mirrored the expression
of this protein in the parental cells, whereas the
exosomal expression levels of CD19, CD20, and
CD45 were more limited in preenriched exosomes
compared with the more or less abundant expression
in the host cells (Figure 3C; compare with Figure 1A).852CD19 was only detected in preenriched exosome
samples from SUDHL-6 cells. CD45 was not de-
tected in preenriched exosome samples from Ramos
cells. CD20 was only detected in preenriched exo-
some samples from SUDHL-4 and SUDHL-6 cells
(Figure 3C). The expression of the general exosome
markers (CD63 and CD81) in preenriched exosome
samples had a pattern similar to total cell samples,
although the expression levels of CD81 was some-
what different (Figure 3A; compare with Figure 1A).
Exosomes released from SUDHL-6 cells had strong
staining for CD81 but low expression of CD63. In
contrast, exosome samples from SW480 had high
expression of CD63 and low expression of CD81.
Precipitated exosomes were also analyzed for possibleVolume 36 Number 6
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Figure 2. Analysis of precipitated exosomes. (A) Precipitated extracellular vesicles (EVs) from SW480 culture
media were analyzed by NanoSight LM10. The size distribution of total EV precipitate resuspended
in phosphate-buffered saline is shown. (B) Precipitated exosomes released from SW480 cells were
analyzed for the content of typical exosomal mRNA and ribosomal RNA (GAPDH and 18S) and
microRNAs (ACTB, Let7a, and miR16) by real-time quantitative polymerase chain reaction. Mean
(SD or SEM) threshold cycle (Ct) values for 3 independent experiments are shown (n ¼ 3). (C)
Immunolabeling of exosomes derived from 4 different B-cell lymphoma cell lines (Ramos, SUDHL-4,
SUDHL6, and Ros-50) and SW480 cells. Preenriched exosomes were transferred to copper grids
and immunostained with mouse anti-human CD81 followed by rabbit anti-mouse antibody and
colloidal gold coated with protein A (10 nm). Samples were stained with uranyl acetate. One of 3
representative experiments is shown. Scale bar ¼ 100 nm.
M.P. Oksvold et al.contamination from intracellular nonexosomal proteins.
The heat shock protein gp96 is constitutively expressed
and located in the lumen of the endoplasmic reticulum,
and the expression of this protein was analyzed in our
precipitated exosomes derived from B-cell lymphomaJune 2014and SW480 cell lines. gp96 was not detected in any of
the exosome samples but was highly expressed in cell
lysates (Figure 3D), indicating that precipitated exosomes
are not contaminated by unwanted intracellular proteins
or endoplasmic reticulum fragments.853
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Figure 3. Expression of B-cell surface proteins and exosomal markers in preenriched exosomes. (A)
Precipitates from complete RPMI media and media from SUDHL-4 and SW480 cells were lysed
and processed for Western immunoblotting analysis. Expression of the exosomal proteins CD81
and CD63 were analyzed. One of 3 representative experiments is shown. (B) Exosomes from Ros-
50 cells preenriched by ultracentrifugation (UC) or precipitation were analyzed by Western
immunoblotting with antibodies against CD81 and CD63. Precipitates from complete RPMI media
were used as the negative control. One of 3 representative experiments is shown. (C) Preenriched
exosomes in media from 4 different B-cell lymphoma cell lines and SW480 cells were lysed and
processed for Western immunoblotting analysis. Expression of the B-cell surface proteins (CD19,
HLA-DR, CD45, and CD20) and exosomal proteins (CD9, CD63, and CD81) was analyzed. One of
3 representative experiments is shown. (D) Precipitates were also analyzed for possible
contamination of an irrelevant endoplasmic reticulum protein (gp96). Total cell lysate (Ramos)
and precipitates from the indicated cell lines were analyzed by Western immunoblotting against
gp96 in addition to HLA-DR and CD45. One of 3 representative experiments is shown.
Clinical TherapeuticsAnalysis of Exosome Subpopulations
The standard method for exosome sample prepa-
ration is ultracentrifugation. A challenge with this
method is lack of speciﬁcity in terms of type of
vesicles. Often, the vesicles obtained by this method
have a heterogeneous size distribution, indicating that
other vesicles are coenriched.51 To increase the sensiti-
vity, remove potential protein aggregates enriched
together with EVs, and possibly isolate subpopula-
tions of exosomes, we applied immunomagnetic
separation to isolate exosomes that expressed CD63
and CD81 from cell culture media. Before a detailed
Western immunoblotting and ﬂow cytometric analysis854of exosomes isolated with immunomagnetic beads, we
analyzed the magnetic bead–bound exosomes at the
ultrastructural level. We also compared exosomes
isolated by ultracentrifugation and precipitation after
capture on anti-human CD81 antibody–coated beads.
Ultrathin sections of anti-human CD81 beads prein-
cubated with exosomes derived from SW480 cell
cultures were made and subjected to electron micro-
scopy to visualize the efﬁciency of exosome docking
(Figure 4). The exosomes observed had a narrow size
distribution (approximately 100 nm), similar to what
has been previously reported.19,51 Exosomes isolated
by ultracentrifugation (Figure 4A) and precipitationVolume 36 Number 6
Dynabeads
Dynabeads 200 nm
200 nm
A
B
Figure 4. Transmission electron microscopy of
CD81þ exosomes. CD81þ exosomes
from SW480 cells were isolated by
anti-CD81 magnetic beads, and sec-
tions of complexes of beads and
CD81þ exosomes were analyzed by
electron microscopy. (A) CD81þ exo-
somes were isolated from exosomes
preenriched by ultracentrifugation. (B)
CD81þ exosomes were isolated from
preenriched precipitated extracellular
vesicles. Arrows indicate typical exo-
somes located at the bead surface.
Scale bar ¼ 200 nm.
M.P. Oksvold et al.(Figure 4B) were comparable in terms of size and mor-
phologic features, although the exosomes preenriched
by ultracentrifugation appeared somewhat more hetero-
geneous in terms of size. The exosomes appeared
electron dense, spherical, and evenly distributed as
single structures (no aggregates) at the surface of the
magnetic beads. The density of exosomes was pro-
portional to the number of exosomes present in the
sample solution (data not shown).
Exosome capture on immunomagnetic beads al-
lowed us to provide a docking surface for the exo-
somes required for downstream ﬂow analysis and for
enrichment of CD63þ and CD81þ human exosomes
for Western immunoblotting analysis. A total of 9
B-cell surface proteins were analyzed for expression inJune 2014subpopulations of exosomes. The expression levels of
the B-cell surface proteins CD19, CD20, CD45, and
HLA-DR were low on exosomes compared with the
preenriched exosome samples (Figures 5A, 5B, 5C,
and 5D). Of interest, CD45 was not detected in
exosome samples. For CD63þ exosomes, HLA-DR
was the only B-cell surface protein that was detected
and mainly in media from Ros-50 cells (Figure 5A;
quantiﬁcation in Figure 5B). CD19, CD20, and HLA-
DR were detected in CD81þ exosomes from SUDHL-
6 cells (Figure 5C; quantiﬁcation in Figure 5D).
In addition, HLA-DR was detected in CD81þ exo-
somes from Ros-50 cells (Figure 5C). The low abun-
dance of B-cell surface proteins was partly reﬂected by
the expression of exosome markers. CD81 and CD63
were detected in all exosome samples but at highly
variable relative expression levels. For the exosomes
isolated with anti-human CD81 beads, high expres-
sion of CD81 was seen in SUDHL-6 and Ros-50
exosomes, whereas high expression of CD63 was only
seen in Ros-50 exosomes (Figure 5A and 5C). The
exosomes isolated with anti- human CD63 beads re-
vealed a more uniform relative expression of CD81
versus CD63 for all lymphoma cell lines. However, of
the 4 B-cell lymphoma cell lines, only Ros-50–derived
exosomes had high CD63 expression levels. We also
compared bead isolation of CD81þ exosomes from
ultracentrifuged and precipitated EVs and analyzed
the samples for the expression of CD81 and CD63.
The expression level of CD81 and CD63 was com-
parable between samples that were either ultracentri-
fuged or precipitated initially (Figure 5E).
Analysis of CD81þ Exosomes by Flow cytometry
We proceeded with isolation and downstream ﬂow
cytometric analysis of CD81þ exosomes. The exo-
some size precludes analysis by FACS alone given the
limited resolution of the ﬂow cytometer. Therefore, a
solid support at a size detectable by ﬂow cytometry is
required. To obtain a strong ﬂow signal, the concen-
tration of magnetic beads was kept low. In this way,
each magnetic bead was loaded with sufﬁcient exo-
somes. The forward and side scatterplot revealed how
the magnetic beads appear in ﬂow cytometry and how
the gating is performed (Figure 6A). The ﬂuorescence
histogram reveals the background median ﬂuorescence
intensity of the magnetic beads. Immunomagnetic iso-
lation of exosomes and staining with isotypic antibody
revealed a similar proﬁle, indicating that background855
HLA-DR5
R
el
at
iv
e
ex
pr
es
si
on
 (
O
D
)
R
el
at
iv
e
ex
pr
es
si
on
 (
O
D
)
R
el
at
iv
e
ex
pr
es
si
on
 (
O
D
)
R
el
at
iv
e
ex
pr
es
si
on
 (
O
D
)
4
3
2
1
20 CD19
HLA-DR
CD20
15
10
5
80
60
20
15
10
5
IgG
IgG
CD63
CD63
CD81
CD81
HLA-DR
CD19
CD45
CD20
CD9
HLA-DR
CD19
B
-c
el
l m
ar
ke
rs
Ex
os
om
e 
m
ar
ke
rs
B
-c
el
l m
ar
ke
rs
Ex
os
om
e 
m
ar
ke
rs
Anti-CD63 bead isolated
A
C
E
D
B
Anti-CD81 bead isolated
CD45
CD20
CD9
CD81
CD63
Ros-50
40
20
Ra
m
os
SU
D
H
L-
4
SU
D
H
L-
6
Ro
s-
50
SW
48
0
Ra
m
os
M
ed
ia
UC Pr
ec
ipi
tat
ion
SU
D
H
L-
4
SU
D
H
L-
6
Ro
s-
50
SW
48
0
Ra
m
os
SU
D
H
L-
4
SU
D
H
L-
6
Ro
s-
50
SW
48
0
Figure 5. Expression of B-cell surface proteins and exosomal markers on exosomes. (A–D) CD63þ (A,
quantification in B) and CD81þ (C, quantification in D) exosomes were immunoisolated using
anti-CD63 and anti-CD81 magnetic beads, respectively. Exosomes were lysed and processed for
Western immunoblotting analysis. Expression of the B-cell surface proteins (CD19, HLA-DR, CD45,
and CD20) and exosome markers (CD9, CD81, and CD63) were analyzed. IgG heavy chain was
applied as the loading control. One of 3 representative Western immunoblots is shown. Quantifica-
tion of B-cell surface antigens after isolation with anti-CD63 beads and anti-CD81 beads is presented
in B and D, respectively. Mean (SEM) expression levels were measured as optical density (OD) and
related to control using Image Lab software (n ¼ 3). (E) Exosome isolated using anti-CD81 beads
from media, ultracentrifugation (UC), and precipitation were analyzed. Samples were analyzed for the
expression of CD81 and CD63 by Western immunoblotting.
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Figure 6. Flow cytometric analysis of exosomes isolated with magnetic beads. Exosomes were immunoisolated from
preenriched exosome samples using magnetic beads coated with anti-human CD81. Exosomes were stained
for B-cell surface antigens (CD20 HLA-DRD22, CD23, CD24, CD37, and CD40) and exosomal antigens
(CD63 and CD81) followed by flow cytometric analysis and presented as median fluorescence intensity
(MFI). (A) Scatterplot and fluorescence histogram of anti-CD81 beads in the absence of exosomes labeled
for CD81 (left), anti-CD81 beads with exosomes stained with irrelevant fluorescent antibody (middle), and
anti-CD81 beads with exosomes stained for CD81. (B) CD81þ exosomes were isolated with magnetic
beads coated with anti-human CD81 antibodies followed by staining of CD20 and HLA-DR in addition to
the exosomal antigens CD81 and CD63. One of 3 representative experiments is shown. (C) Mean (SEM)
quantification of the expression of CD81, CD63, CD20, and HLA-DR is shown (n ¼ 3). (D) Expression of
the B-cell surface proteins CD22, CD23, CD24, CD37, and CD40 on CD81þ exosomes from the indicated
B-cell lymphoma cell lines and SW480. Gating for single beads and MFI (arcsinh ratio of medians relative to
irrelevant control) are shown. Beads were applied as negative control. One of 3 representative experiments is
shown. FSC-A ¼ forward-scattered light ; PE ¼ phycoerythrin; SSC-A ¼ side-scattered light.
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Clinical Therapeuticsstaining equals autoﬂuorescence of the magnetic beads
(Figure 6A) compared with the speciﬁc signal obtained
by relevant CD81 staining of bead isolated exosomes
(Figure 6A). Furthermore, additional control experi-
ments were performed (see the Supplementary Figure in
the online version at http://dx.doi.org/10.1016/j.clinthera.
2014.05.010). Exosomes derived from the 4 different B-
cell lymphoma cell lines in addition to SW480-derived
exosomes were isolated with CD81 beads. After bead
isolation, the exosomes were stained with anti-CD81 PE
in the presence or absence of a blocking agent (normal
mouse IgG). No signiﬁcant difference in CD81 staining
was observed in the presence or absence of a blocking
reagent as indicated by ﬂow cytometry (see the
Supplementary Figure in the online version at http://dx.
doi.org/10.1016/j.clinthera.2014.05.010). In addition,
exosomes derived from 4 different B-cell lymphoma cell
lines in addition to SW480-derived exosomes were
isolated to target CD81 and stained with anti-CD81
PE (subclass IgG1) or anti-HLA-DR FITC (subclass
IgG2b) in the presence or absence of blocking reagent
(normal mouse IgG). No signiﬁcant difference in CD81
or HLA-DR signal were observed (see the Supplementary
Figure in the online version at http://dx.doi.org/10.1016/
j.clinthera.2014.05.010).
CD81þ exosomes were surface stained with anti-
bodies against the B-cell surface proteins CD20 and
HLA-DR, in addition to the exosome markers CD81
and CD63. The expression pattern of B-cell surface
proteins and exosome markers revealed by Western
immunoblotting analysis (Figure 5) was conﬁrmed by
FACS (Figures 6B and 6C). Figure 6B shows the ﬂow
cytometric analysis of a typical CD81 PE staining. The
quantiﬁcation of staining for CD81, CD63, CD20, and
HLA-DR on isolated CD81þ exosomes is presented in
Figure 6C. For the CD81þ isolated exosomes, samples
from SUDHL-6 and Ros-50 had the most pronounced
expression of CD81, whereas expression of CD63 was
highest on exosomes from Ros-50 and SW480 cells
(Figure 6C) conﬁrmed by Western blotting (Figure 5C).
Five other B-cell surface antigens (CD22, CD23, CD24,
CD37, and CD40) were analyzed for expression on
CD81þ exosomes by ﬂow cytometry. CD24 was ex-
pressed in exosomes derived from SUDHL-6 and Ros-
50, whereas CD37 was highly expressed on exosomes
from all cell lines, representing 4 different types of
B-cell lymphoma (Figure 6D). These results are similar
to the expression observed in the host cells (Figure 1B).
However, among the other B-cell surface proteins,858there are examples of high cellular expression and
low or negative exosome expression (eg, CD22 and
CD40). These ﬁndings illustrate that B-cell lymphoma–
derived exosomes encompass variable expression of
both B-cell surface proteins and classic exosomal
markers. CD81 seemed to be the most widely expressed
exosomal protein on exosomes released from B-cell
lymphoma cells. CD81þ exosomes were found to ex-
press CD19, CD20, HLA-DR, CD24, and CD37. All
these B-cell surface proteins represent interesting targets
for immunotherapy of B-cell lymphoma and other
hematologic malignant neoplasms.
EVs from Lymphoma Cells Intercept
rituximab-induced CDC
Ligation of rituximab to CD20 exerts cytotoxic
effects by induction of both CDC and antibody-
dependent cell-mediated cytotoxicity. It has recently
been found that ultracentrifuged exosomes from lym-
phoma cells can reduce rituximab-induced CDC in
lymphoma cells. To know whether precipitated EVs
had a similar interception of antibody-induced CDC,
we applied a rituximab-mediated CDC assay to mea-
sure effects of adding EVs to lymphoma cells. SUDHL-
6 cells treated with rituximab (1 μg/mL) alone had a
47% reduction in viability compared with untreated
cells (Figure 7). When cells were preincubated with
EVs (10-20 μg/mL) from CD20 SW480 cells before
incubation with rituximab, no increase in viability was
detected. In contrast, a signiﬁcant improved viability
(22% reduction) was measured when CD20þ EVs
from SUDHL-6 cells were added to the culture.
DISCUSSION
A mean of 1 mL of blood serum, derived from healthy
donors, contains approximately 1012 exosomes. De-
pending on the disease, the number of exosomes can
ﬂuctuate. Concentration of exosomes in the blood-
stream and all other body ﬂuids is extremely high.52
The aim of this study was to examine exosomes
released from different B-cell lymphoma cell lines in
terms of expression of B-cell surface antigens. We
found that the level of typical exosomal markers and
common B-cell markers diverge signiﬁcantly, depend-
ing on the host cell origin. We have compared preen-
riched EVs with the more pure exosome fraction
expressing CD81 and CD63 and also analyzed differ-
ent subpopulations of exosomes. Our data clearly
indicate a signiﬁcant difference in protein compositionVolume 36 Number 6
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Figure 7. Extracellular vesicle (EV)–mediated rescue
of lymphoma cells from rituximab-in-
duced complement-dependent cytotoxi-
city. SUDHL-6 cells in culture at 1 
106 cells/mL were added to EVs (exosome
[EXO], 10-20 mg/mL) from either SW480
or SUDHL-6 cells, followed by the addi-
tion of rituximab (1 mg/mL), and incu-
bated for 1 hour. Viability was analyzed
using the CellTiter 96 Aqueous One Solu-
tion reagent in 96-well plates and shown
as mean (SEM) (n ¼ 3, *P ¼ 0.0005).
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and importantly the existence of subpopulations of
exosomes derived from the same cell type expressing
their own characteristic panel of proteins. Exosomes
derived from lymphoma B cells contain CD19, CD20,
CD24, CD37, and HLA-DR, with a large heterogeneity
among the different cell lines. These proteins represent
interesting targets for immunotherapy, and in our work
we found that CD20þ EVs can intercept anti-CD20
(rituximab)–mediated cytotoxicity in lymphoma B cells.
In a recent review of EVs in cancer therapy,53 one of
the outstanding questions that was raised was whether
subpopulations of EVs serve different physiologic func-
tions. We believe that the immunomagnetic separation
may represent one of the tools to study subpopulations of
exosomes and to solve this important question. Enrich-
ment of vesicles as small as exosomes is a challenging
task. Such workﬂows often involve the use of ultracentri-
fugation with a sequential increase in centrifugal forces so
that cellular components can stepwise be removed from
the sample. In the ﬁnal steps of such an elaborate
protocol, exosomes are pulled out after centrifugation
at 100.000g for42 hours.14,22 Exosomes obtained with
ultracentrifugation appear heterogeneous in terms of size
distribution, including 40- to 100-nm diameter vesicles,June 2014but larger vesicles are also present.51 In addition to conta-
mination of larger vesicles, larger protein aggregates
might coaggregate with the target vesicles. By ﬂoating
the exosomes on a density gradient exploiting the
exosomes’ buoyant density during ultracentrifugation,
protein aggregates can be removed from the exosome
preparation. Exosomes enriched using density gradient
centrifugation have a more homogenous appearance in
terms of size distribution.51 The protein proﬁle revealed
fewer proteins compared with exosomes prepared by
ultracentrifugation, indicating that exosomes prepared by
ultracentrifugation may be contaminated. As an alterna-
tive to an ultracentrifugation-based exosome enrichment,
a precipitation-based exosome enrichment method might
be used equivalent to precipitation of viruses and other
smaller particles.53,54 To increase the purity, Tauro et al51
concluded that immunomagnetic separation was the best
method for exosome capture. However, the immuno-
magnetic beads they used are in the nanometer range, a
challenge in terms of resolution if the downstream appli-
cation is ﬂow cytometry, and it also requires an ultra-
centrifugation step to enrich the exosomes. This can be
solved by providing a larger solid surface for the
exosomes to dock, which can easily be observed in the
ﬂow cytometer. Clayton et al19 developed a rapid and
versatile technique for exosome isolation and ﬂow ana-
lysis. Anti–major histocompatibility complex class II anti-
bodies were coated to the surface of 4.5-mm magnetic
beads. This bead size gives us a recognizable forward and
side scatter pattern that allows for gating of single mag-
netic beads coated with exosomes for labeling analysis.
The expression of B-cell surface proteins was limited in
immunoisolated CD81þ and CD63þ exosomes compa-
red with microvesicles, indicating that by immunoisolat-
ing CD81þ and CD63þ vesicles you will lose additional
EVs that express B-cell surface proteins. These EVs can
have the same potential in terms of immunotherapy
interference compared with CD81þ and CD63þ exo-
somes. Yoshioka et al50 have recently suggested CD9 and
CD81 to be the most suitable exosome markers. How-
ever, CD9 is not expressed in all cell types (eg, mature
B cells as reported here). We characterized exosomes
derived from different B-cell lymphoma cell lines. This
study provides evidence of release of CD81þ exosomes
expressing CD19, CD20, CD24, CD37, and HLA-DR
from B-cell lymphoma cells. The exosomal expression
of CD19 and CD20 was weak compared with the total
EV pool, and CD45 was not detected in exosomes but
well expressed in EVs. Our study of immunoisolated859
Clinical Therapeuticsexosomes indicates a heterogeneous level of exosome
release and expression of exosomal B-cell surface proteins
among different B-cell lymphoma cell lines, representing
different B-cell lymphoma subtypes.
Previous experiments have suggested a possible use
of exosomes in cancer immunotherapy.1,55 However, it
has also been suggested that instead of augmenting
immune responses exosomes mainly suppress anti-
tumor immune responses.31,56 Exosomes may therefore
have positive and negative effects in terms of cancer
progression. A deeper characterization of exosomes
and their protein composition therefore justiﬁes further
studies of these vesicles to understand their relevance
for tumor growth and metastasis and the molecular
mechanisms mediating release of tumor cell–derived
exosome and uptake in recipient cells.
In hematologic malignant neoplasms for which
antibody-based cancer therapy is especially promising,
it will be an advantage to characterize the expression of
B-cell surface antigens on circulating exosomes. Exoso-
mal CD19, CD20, CD37, and HLA-DR might intercept
immunotherapy. We describe this for CD20, and a simi-
lar scenario may also be possible for antibodies against
CD19, CD37, and HLA-DR, which currently are in
clinical trials.33,39,57 Although our work is supported by
earlier ﬁndings of Aung et al,31 who reported that B-cell
surface markers are expressed on EVs released from
B-cell lymphoma cell lines, there are also some discrep-
ancies. Whereas we detect exosomal CD20 only in the
SUDHL-6 cell line and not in the Ramos, SUDHL-4, or
Ros-50 cell lines, Aung et al detected CD20þ exosomes
from SUDHL-4 cells. However, we were able to detect
CD20þ vesicles from SUDHL-4 and SUDHL-6 cells in
our total EV precipitate (Figure 3). A signiﬁcant diffe-
rence in these 2 studies is the sample preparation of the
EVs. Whereas Aung et al31 used ultracentrifugation, we
immunoisolated CD81þ and CD63þ exosomes. The
vesicles we are studying therefore represent a cleaner
population of exosomes. Aung et al31 also detected CD9
in exosomes released from SUDHL-4. This is surprising
because CD9 should be expressed on pre-B cells and not
on mature B-cells.58
CONCLUSION
We found a large heterogeneity among the different
B-cell lymphoma cell lines in terms of release of
exosomes and their expression of B-cell surface anti-
gens. B-cell surface antigens were detected on vesicles
from a total EV precipitate and on immunoisolated860CD81þ and CD63þ exosomes. CD81þ exosomes ex-
pressed CD19, CD20, CD24, CD37, and HLA-DR,
whereas HLA-DR was detected on CD63þ exosomes.
CD22, CD23, CD40, and CD45 were not detected on
exosomes, although most of them are widely expressed
in the B-cell lymphoma host cells. Similar to CD20,
expression of B-cell surface antigens may intercept
immunotherapy directed against these antigens, and it
is therefore important to be aware of this and to
further characterize exosomes released from B cells.
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